P. C. Lucas

WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line model

The paper introduces a new invasive lobular carcinoma cell line, WCRC-25, and demonstrates its molecular features and therapeutic response to PI3K/AKT inhibition.

Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations

This study uses spatial molecular profiling to show that mixed invasive ductal-lobular breast cancers have distinct molecular subtypes, oncogenic signatures, and mutations in different tumor regions, leading to prognostic uncertainty and therapeutic challenges.

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

This study identifies 11 oncogenic pathways associated with immune exclusion and ICI resistance in acral melanoma, suggesting therapeutic targets for immunotherapy combinations.

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis

This study identifies ESR1 mutations as drivers of breast cancer metastasis by altering cell adhesion and migration through genomic and transcriptomic reprogramming.

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathways

This study shows that Ewing sarcoma cells with germline BARD1 mutations are sensitive to PARP inhibitors and that PARP inhibition increases PD-L1 expression, suggesting potential for combination immunotherapy.

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences

This study analyzes acquired mutations and transcriptional changes in long-term estrogen-deprived breast cancer recurrences, identifying common genetic and expression alterations associated with endocrine resistance.

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

The paper compares immune cell infiltration in primary and metastatic breast tumors, finding reduced immune cell abundance but increased M2-like macrophages in metastases.

Targeted mutation detection in breast cancer using MammaSeqTM

The paper develops MammaSeq, a targeted NGS panel for detecting clinically actionable mutations in breast cancer, showing it identifies actionable variants in 48% of solid tumors and 29% of cfDNA samples.

Exome-Capture RNA-Sequencing Of Decade-Old Breast Cancers And Matched Decalcified Bone Metastases Identifies Clinically Actionable Targets

This study uses exome-capture RNA-sequencing on decade-old breast cancer specimens and matched bone metastases to identify clinically actionable gene expression changes in metastatic progression.